Breaking
Your Income Partners
Author

admin

Browsing
Investing

Noble Announces Non-Brokered Private Placement

(TheNewswire)

Noble Mineral Exploration Inc.

TORONTO TheNewswire – November 10, 2025 Noble Mineral Exploration Inc. (‘ Noble ‘ or the ‘ Company ‘) (TSXV: NOB,OTC:NLPXF) (OTCQB: NLPXF) is pleased to announce that it is undertaking a non-brokered private placement (the ‘ Private Placement ‘) on a best efforts basis, involving the issuance of up to 18,000,000 flow-through common share units (‘ FT Units ‘) at a price of $0.06 per unit, subject to an increase of up to 25% at the discretion of Noble should investor interest warrant doing so. The gross proceeds to be raised are up to $1,080,000 (before fees and expenses), subject to increase as noted. Each FT Unit will be comprised of one common share to be issued as a ‘flow-through share’ and one-half non-flow-through common share purchase warrant, each full warrant will be exercisable for two years for one common share in the capital of the Company at an exercise price of $0.10 per common share.

The Company may pay compensation to brokers providing assistance with the private placement, which could consist of a cash commission of up to 7% of the amount raised through the brokers’ assistance and/or broker warrants exercisable for up to 7% of the number of FT Units placed (the ‘ Broker Warrants ‘).  Each Broker Warrant would be exercisable for two years for one common share of the Company at an exercise price of $0.06 per share.

The securities to be issued in this Private Placement are subject to a four month hold period.

The Private Placement is subject to customary closing conditions, including the approval of the TSX Venture Exchange. Noble intends to use the proceeds raised through the Private Placement to fund exploration expenditures on the Company’s properties.

About Noble Mineral Exploration Inc.

Noble Mineral Exploration Inc. is a Canadian-based junior exploration company, which has holdings of securities in Canada Nickel Company Inc., Homeland Nickel Inc., East Timmins Nickel Inc. (20%), and its interest in the Holdsworth gold exploration property in the area of Wawa, Ontario.

Noble holds mineral and/or exploration rights in ~70,000ha in Northern Ontario and ~14,000ha elsewhere in Quebec upon which it plans to generate option/joint venture exploration programs.

Noble holds mineral rights and/or exploration rights in ~18,000 hectares in the Timmins-Cochrane areas of Northern Ontario known as Project 81, ~2,215 hectares in Thomas Twp/Timmins, as well as an additional 20% interest in ~38,700 hectares in the Timmins area. Project 81 hosts diversified drill-ready gold, nickel-cobalt and base metal exploration targets at various stages of exploration. Noble also holds ~4,600 hectares in the Nagagami Carbonatite Complex and~3,200 hectares in its Boulder Project, both near Hearst, Ontario.  In addition, it holds the following projects in Quebec:  ~3,700 hectares in its Buckingham Graphite Property, ~10,152 hectares in its Havre St Pierre Nickel, Copper, PGM property, ~1,573 hectares in its Cere-Villebon Nickel, Copper, PGM property, a ~569 hectare Uranium/Rare Earth property that it refers to as the Chateau property, a ~461 hectare Uranium/Molybdenum property that it refers to as the Taser North property, and ~ 4,465 hectares in the Mehmet rare earth property in Northern Quebec. Noble’s common shares trade on the TSX Venture Exchange under the symbol ‘NOB.’

More detailed information on Noble is available on the website at www.noblemineralexploration.com .

Cautionary Note and Statement Concerning Forward Looking Statements

This press release contains certain information that may constitute ‘forward-looking information’ under applicable Canadian securities legislation.  Forward-looking information is necessarily based upon several assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information.  Factors that could affect the outcome include, among  others:  future prices and the supply of metals, the future demand for metals, the results of drilling, inability to raise  the money necessary to incur the expenditures required to retain and advance the property, environmental liabilities  (known  and  unknown), general business, economic, competitive, political and social uncertainties, results of  exploration programs, risks of the mining industry, delays in obtaining governmental approvals, failure to obtain  regulatory or shareholder approvals.  There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.  Accordingly, readers should not place undue reliance on forward-looking information.  All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof.  Noble disclaims any intention or obligation to update or revise any forward-looking information, whether because of new information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.   No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Contacts:

H. Vance White, President

Phone:        416-214-2250

Fax:        416-367-1954

Email: info@noblemineralexploration.com

Investor Relations

Email: ir@noblemineralexploration.com

Copyright (c) 2025 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com
Keep Reading
Politics

Mike Johnson eyes Wednesday vote with end of government shutdown in sight

Speaker Mike Johnson, R-La., is anticipating the House could vote to end the government shutdown as early as Wednesday, Fox News Digital is told.

The House GOP leader held a lawmaker-only call late on Monday morning where he urged Republicans to return to Washington as soon as possible for what is expected to be just a single day of voting before a full session week begins on Nov. 17.

‘We’re going to plan on voting, on being here, at least by Wednesday,’ Johnson said, Fox News Digital was told. ‘It is possible that things could shift a little bit later in the week, but right now we think we’re on track for a vote on Wednesday. So we need you here.’

He told House GOP lawmakers that the earliest possible vote he could anticipate would be on Wednesday morning, but he later shifted that estimate to the afternoon or evening that day given some Republicans’ schedules this week.

At least several House lawmakers would have to shift district events marking Veterans Day on Tuesday to return by Johnson’s deadline.

One Republican on the call said they would fly to D.C. early on Wednesday morning due to a large-scale event with military veterans the day prior, Fox News Digital was told.

Johnson signaled the House would not move to fast-track the legislation via suspension of the rules, which would bypass procedural hurdles in exchange for raising the passage threshold to two-thirds of the chamber.

Fox News Digital was told the House Rules Committee, the final barrier before a chamber-wide vote, could consider the legislation as early as Tuesday.

It’s not a surprising move, given House Democratic leaders’ opposition to the bill.

Several House Democrats have also declared they will vote against the measure because it does not include any guarantees on extending COVID-19 pandemic-era enhanced Obamacare subsidies that are set to expire at the end of this year.

The House could send President Donald Trump a bill to end the government shutdown as early as Wednesday evening if their current estimates hold.

But their movements will largely depend on what happens in the Senate, where eight Democrats joined Republicans Sunday night to break a filibuster on the shutdown’s 40th day.

But there are several votes left and procedural roadblocks that could be weaponized that could grind the Senate’s march to advance its package to the House to a halt. If all 100 senators agree to fast-track the process, the package could move as quickly as Monday night.

But if not, the bipartisan plan could stagnate in the upper chamber for several days.

Senate Majority Leader John Thune, R-S.D., was optimistic that the Senate could finish its work Monday night but said that would be up to Senate Democrats.

‘Obviously, there are objections from the left, but as long as the votes are there to proceed, we will move forward, and hopefully without a lot of disruption or delay or fanfare right now,’ Thune said. ‘The point is, we are on a path to get the government reopened, and we should try to get it done as soon as possible.’

Schumer didn’t say whether Democrats would block any attempt to move the process along but did blame President Donald Trump and Republicans for the shutdown, which stretched into its 41st day on Monday.

Whether Senate Democrats are in line with a cohesive strategy to block the package remains to be seen. But Sen. Ruben Gallego, D-Ariz., told Fox News Digital that he ‘didn’t hear anything’ about objections or blocks during the Democratic caucus’ closed-door meeting Sunday night.

This post appeared first on FOX NEWS
Keep Reading
Investing

InMed Pharmaceuticals

Investor Insight

InMed is a pharmaceutical drug development company advancing proprietary small-molecule drugs in Alzheimer’s and ophthalmology, backed by a revenue-generating manufacturing subsidiary. The company is an undervalued opportunity with cash exceeding market capitalization and multiple upcoming catalysts.

Overview

InMed Pharmaceuticals (NASDAQ:INM) is a biopharmaceutical company with a differentiated business model: advancing innovative therapeutic programs in Alzheimer’s, ophthalmology and dermatology, while generating recurring revenue through its BayMedica manufacturing division. This structure offers investors exposure to pharmaceutical innovation with mitigated financing risk, a rare combination among small-cap biotech firms.

The company’s lead drug candidate, INM-901, takes a new and broader approach to treating Alzheimer’s disease. Instead of focusing on just one suspected cause – a protein in the brain called amyloid beta – this drug is designed to act on several key processes that drive the disease. In preclinical studies, INM-901 has shown that it can protect brain cells, reduce inflammation, clear harmful protein buildup, and help new nerve connections form. These results led to improvements in both brain health and behavior in research models. This “multi-pathway” approach reflects the latest thinking in Alzheimer’s research, where major pharmaceutical companies are moving toward treatments that target the disease from multiple angles.

InMed’s BayMedica subsidiary manufactures rare cannabinoids via chemical synthesis, rather than plant extraction, ensuring purity, consistency and scalability. The business generates approximately $5 million in annual revenue and ~40 percent gross margins, selling to the global health and wellness ingredient markets. This dual business model gives InMed a cash flow-supported R&D engine, enhancing sustainability and valuation resilience.

Key Business Segments

Pharmaceuticals

InMed’s pharmaceutical programs are focused on developing new, small molecule medicines that address serious diseases where current treatments fall short. These drug candidates are designed to work on multiple disease pathways, offering a more comprehensive approach than traditional single-target drugs. The company’s current programs target Alzheimer’s disease, dry age-related macular degeneration (AMD), and a rare skin disorder called epidermolysis bullosa (EB). Each program is supported by strong preclinical or clinical data and aims to move into the next stage of development in the near term.

Highlights

  • INM-901 (Alzheimer’s disease): INM-901 is being developed as a potential new treatment for Alzheimer’s disease, a condition that currently has no cure. Unlike many past approaches that focused only on a single cause, INM-901 targets several key processes that contribute to Alzheimer’s, including protecting brain cells, reducing inflammation, lowering harmful protein buildup, and supporting the growth of new nerve connections. In animal studies, the drug has shown improvements in brain inflammation and memory-related behavior, suggesting a broad protective effect. The program is now advancing IND-enabling activities, an important stage in translating INM-901’s scientific promise into clinical evaluation.
  • INM-089 (Dry AMD): New drug being developed to help slow or prevent vision loss in people with dry age-related macular degeneration, one of the leading causes of blindness in older adults. The drug is designed to protect nerve cells in the eye and reduce inflammation, helping to keep the retina healthy. Laboratory studies have shown its ability to maintain vision-related function and protect retinal tissue. The company has developed a safe and effective eye-injection (intravitreal) formulation, which delivers the drug directly to where it’s needed in the eye. INM-089 is now moving toward the final preclinical studies required before starting human trials.
  • INM-755 (Dermatology / Epidermolysis Bullosa): A topical cream that has completed a Phase 2 clinical trial in patients with epidermolysis bullosa (EB), a rare genetic skin disorder that causes fragile, blistering skin. The study showed the cream was safe, well-tolerated and helped reduce itching, which is a major symptom for EB patients. The company plans to advance this program through partnerships or licensing agreements.

Manufacturing (BayMedica)

InMed’s BayMedica division provides a steady source of revenue and a strong commercial foundation that supports the company’s drug development work. BayMedica specializes in making rare, non-intoxicating cannabinoids, natural compounds originally found in the cannabis plant, but without using the plant itself. Instead, these compounds are produced through biosynthesis and chemical synthesis, highly controlled processes that ensure every batch is pure, consistent and scalable for commercial production.

BayMedica’s ingredients are sold to health, wellness and consumer brands that use them in products such as supplements and topicals. Each cannabinoid has its own unique properties, and BayMedica is helping customers explore their benefits safely and reliably. The division is recognized as a global leader in rare cannabinoid manufacturing, particularly for cannabichromene (CBC), where it is among the largest producers in the world.

Product Portfolio: BayMedica produces several rare cannabinoids, including CBC, THCV, CBT and CBDV, which are known for their unique biological effects.

Financial Performance: In fiscal year 2025, BayMedica generated approximately $4.9 million in revenue, growing by 8 percent year over year, with around 40 percent gross margins and positive net income. These results help fund InMed’s pharmaceutical programs and reduce the need for frequent financing, a major advantage for a small-cap biotech.

Management Team

Eric Adams – Chief Executive Officer and President

Eric Adams has led a comprehensive transformation of InMed Pharmaceuticals’ leadership team and governance structure, reconstituting the board of directors and executive management while raising more than $35 million in capital to support operations and growth. With more than 25 years of experience in the biopharmaceutical industry, Adams brings extensive expertise in corporate development, capital formation, global market expansion, mergers and acquisitions, licensing and corporate governance.

Michael Woudenberg – Chief Operating Officer

Michael Woudenberg brings deep expertise in the development, technology transfer and commercialization of active pharmaceutical ingredients (APIs) and drug products. Before joining InMed in 2018, Woudenberg held senior roles at 3M, Cardiome Pharma and Arbutus Biopharma, and most recently served as managing director of Phyton Biotech. His extensive experience spans process and formulation development from laboratory and pre-clinical stages through all phases of clinical development, leading to validated, approved, and commercially manufactured APIs and drug products.

Netta Jagpal – Chief Financial Officer

Netta Jagpal brings over 20 years of financial leadership experience, primarily in the biotechnology sector. Before joining InMed, she served as vice-president, financial reporting and compliance at D-Wave Systems (NYSE:QBTS), where she led the finance team through its initial public offering. Jagpal spent 11 years at Zymeworks (NYSE:ZYME) in progressive finance roles, including senior director, finance and corporate controller, and also held positions at Angiotech Pharmaceuticals and Ernst & Young. She is a chartered professional accountant and holds a Bachelor of Business Administration in Accounting and Organizational Behaviour from Simon Fraser University.

Eric Hsu – Senior Vice-president, Pre-Clinical Research & Development

Dr. Eric Hsu brings more than 18 years of scientific leadership experience in gene therapy and biotechnology. Before joining InMed, he held senior roles at enGene, including vice-president of research and vice-president of scientific affairs and operations. His expertise spans gene transfer and expression systems, formulation and process development, intellectual property management, and research partnerships. Hsu has extensive experience leading R&D programs, expanding product pipelines, and overseeing research budgets and timelines.

Colin Clancy – Vice-president, Investor Relations and Corporate Communications

Colin Clancy is an experienced corporate finance and investor relations executive with over 18 years of experience across the pharmaceutical, cannabis, mining and financial services sectors. At InMed Pharmaceuticals, he leads the company’s capital markets engagement and communications strategy. Before joining InMed, Clancy served as vice-president of investor relations at Harvest One Cannabis.

This post appeared first on investingnews.com
Keep Reading
Investing

US Reinstates Uranium as Critical Mineral, Boosting Domestic Producers

The US government has officially added uranium back to the nation’s list of critical minerals in a bid to strengthen domestic energy security and reduce reliance on foreign sources.

The final 2025 List of Critical Minerals, released by the US Geological Survey (USGS), identifies 60 minerals essential to the US economy and national security, including 10 newly added resources such as copper, silver, and uranium.

“In 2017, President Trump set a goal of first identifying and then securing the mineral resources needed to bolster America’s economy and national security. The 2025 List of Critical Minerals provides a clear, data-driven roadmap to reduce our dependence on foreign adversaries, expand domestic production and unleash American innovation,” Interior Secretary Doug Burgum said in a statement.

The designation of uranium recognizes its strategic importance in powering commercial nuclear reactors, fueling US Navy submarines, and supporting defense applications.

Currently, the United States imports over 95 percent of its uranium, a dependence that policymakers view as a critical national security concern.

The announcement has been met with optimism from US uranium producers.

Anfield Energy (TSXV:AEC,OTCQB:ANLDF), which recently held a groundbreaking ceremony at its Velvet-Wood uranium-vanadium mine in Utah, emphasized the significance of the designation.

“This is a transformative moment for both American energy security and Anfield,” said Corey Dias, Anfield CEO. “With uranium now officially classified as a critical mineral, our advanced-stage projects located in both Utah and Colorado potentially stand to benefit from expedited permitting, targeted federal investments, and enhanced market access.

Anfield, which also recently listed on the NASDAQ under the symbol “AEC,” operates a “hub-and-spoke” model centered on its Shootaring Canyon Mill, one of only three conventional uranium mills in the United States.

The company’s Velvet-Wood project alone contains 4.6 million pounds of measured and indicated uranium oxide equivalent. Production is expected to commence in 2026 following expedited federal and state approvals.

Other US uranium producers echoed similar sentiments. Uranium Energy (NYSEAMERICAN:UEC), with hub-and-spoke operations in Texas and Wyoming, said the designation supports expansion of domestic uranium refining and conversion capabilities.

“UEC is heeding that call with ramp-up and development activities at our three licensed hub-and-spoke production platforms,” said CEO Amir Adnani. “In parallel, we’re advancing the United States Uranium Refining & Conversion Corp. to help restore and expand America’s domestic nuclear fuel conversion capabilities.”

Encore Energy (TSXV:EU), which operates the Dewey Burdock In-Situ Recovery project in South Dakota, noted that its facility has been added to the Fast-41 Program for expedited federal permitting.

The program, administered by the Federal Permitting Improvement Steering Council, prioritizes infrastructure and critical mineral projects to accelerate development.

Some federal incentives in the push, which seeks to improve domestic competitiveness, include grants, loans, tax credits, and potential tariffs on imported uranium.

The US government is also advancing critical mineral strategy on the international stage. On Thursday last week, President Donald Trump hosted the leaders of five Central Asian nations—Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan—to further efforts in securing global supply chains and expanding US influence in the resource-rich region.

‘One of the key items on our agenda is critical minerals,’ Trump said. ‘In recent weeks, my administration has strengthened American economic security by forging agreements with allies and friends across the world to broaden our critical mineral supply chains.’

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
Keep Reading
Investing

AI, Energy Transition and COP30 Present New Opportunities for Sustainable Investment

As COP30 convenes in Belém, Brazil, the global urgency to tackle climate change feels sharper than ever.

Meeting ambitious sustainability goals requires mobilizing vast amounts of capital toward clean energy and climate solutions, an endeavor now complicated and accelerated by the surging energy demands of AI technologies. Addressing these evolving needs while advancing climate goals presents both unprecedented challenges and opportunities for investors.

Bruce Kahn, lead portfolio manager at Shelton Capital Management, brings a seasoned voice to this evolving landscape. With over 25 years shaping sustainable equity portfolios and ESG integration, he highlights how renewable energy and innovative investment strategies are critical to powering AI’s growth while advancing climate objectives.

The AI-energy nexus and its investment implications

Kahn underscored a transformative dynamic in the investment landscape: AI’s rapid expansion is driving substantial new energy requirements that existing infrastructure must be ready to accommodate. This convergence creates both risk and opportunity for sustainable investors.

Renewable energy emerges as the fastest and most economically viable option to meet AI’s surging electricity demand.

“If hyperscalers want to have massive data centers, the quickest path to that is going to be deploying renewable energy. Whether that’s in front of the meter or behind the meter, that is the quickest and cheapest way of getting energy,” Kahn said

“There’s still been a lot of talk about nuclear. There’s opportunity there, as well as (with) gas-fired power plants, but those are long-dated situations,” he added, along with challenges around fuel supply. “The quickest way to get power up and running is going to be renewables, and that includes wind. Wind is economical. These projects finance themselves with or without tax credits.”

Khan also cited solar, biofuels and geothermal as cornerstones in this transitioning energy mix. Underlying this transition is a strong demand for the industrial and materials sectors supplying the essential components for renewable infrastructure.

The AI-energy nexus calls for expanded thematic investments, distinct from traditional ESG-focused strategies focused on addressing climate resilience, energy efficiency and industrial transformation related to AI’s pervasive role.

“From a portfolio management and factor management perspective, I have to consider how overweight I am to a factor such as industry, and then an overweight sector, such as industrials and materials. So that becomes a challenge, because that’s where there are a lot of great opportunities, but you know, you have to be very choosy.”

Kahn emphasized the importance of focusing on “core” technology segments, such as fuel enrichment and water quality measurement, which may offer more stable, structural demand and lower volatility compared to early-stage growth technologies.

Reflecting market evolution, Kahn highlighted the growing prominence of infrastructure funds and alternative investment vehicles beyond traditional equities for capturing these themes.

Ongoing innovation in public equities expanding access to smaller growth companies represents a critical frontier for investors seeking exposure to early-stage innovations within the broader energy transition.

Managing portfolio challenges amid technological and geopolitical uncertainty

One key risk Kahn highlights is the potential for slower-than-expected adoption of AI technologies to transform the industrial economy. In this uncertainty, there is also caution against overexposure to assets that might become stranded if energy demand or technology shifts deviate from expectations.

To mitigate this, Shelton Capital focuses on investing in “core” technologies that underlie energy infrastructure and climate solutions, such as fuel enrichment processes and water quality measurement. Climate adaptation sectors like agriculture also feature prominently, reflecting their frontline role in managing climate risks.

Kahn also acknowledges that short-term market volatility and policy shifts create noise, but says they are unlikely to alter the long-term investment trajectory.

“All the data suggests that companies don’t invest balance sheet capital based on four-year or even two-year political wins; they’re investing for 10, 15, 20 years,” he noted. This long-term horizon requires patient, disciplined capital deployment.

“We’re talking to the CEOs of these companies and asking them what their capital plans are. They are not pausing their sustainability initiatives because they’ve proven to themselves that this is a driver of profitability.”

Shelton Capital employs a bottom-up investing philosophy grounded in carefully selected sustainability themes aligned with resilience, human well-being and technological innovation. ESG analysis is integrated as a foundational layer within a broader thematic framework, enabling a comprehensive view of company operations and their contribution to sustainability goals.

Looking ahead: Trends and priorities for COP30 and beyond

COP30 represents a pivotal moment to recognize the intertwined nature of technology advancement, energy infrastructure and climate imperatives.

The immense energy footprint driven by AI technologies presents both daunting challenges and tremendous opportunities within the global climate agenda. The geography of renewable energy deployment is also evolving swiftly, with emerging markets playing a critical role in driving global capacity growth.

“While we may be hamstrung now in the US in the short term, renewable energy is being deployed all over the rest of the world at huge scales,” said Kahn.

Sustainable investment has also emerged as a critical lever to mobilize capital in support of the values of newer generations. Kahn described how deeply embedded sustainability values and significant upcoming wealth transfers position Gen Z and millennials as key drivers of market transformation.

“They’re what I refer to as sustainability native,” he explained. “They kind of came to it naturally. It wasn’t forced on them.

“They are going to have a lot of power, from an investment standpoint, to shape markets, and markets respond to capital,” he added.

Effective climate investing requires a multi-sector, multi-asset approach spanning equity, debt, real estate, commodities and real assets. Investor education and sophisticated portfolio diversification will be pivotal in shaping the future market environment, equipping investors and advisors to align capital with evolving sustainability goals and technological advancement.

Investment managers and advisors must navigate these complexities with agility and insight, steering capital to solutions that drive both financial returns and transformative impact.

As the AI-energy nexus continues to redefine the investment landscape, aligning capital with long-term climate imperatives is no longer optional; it is the blueprint for future value creation.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
Keep Reading
Politics

FDA moves to lift ‘black box’ warnings from hormone therapies for menopause symptoms

The U.S. Food and Drug Administration (FDA) announced it is initiating the removal of ‘black box’ warning labels from hormone replacement therapy (HRT) products used to ease menopause symptoms, a move Commissioner Dr. Marty Makary said is backed by decades of research on the therapy’s benefits and clinical trials that do not support earlier fears linking it to higher breast cancer mortality.

Health and Human Services Secretary (HHS) Robert F. Kennedy Jr. said at a press conference alongside Makary on Monday that the so-called ‘black box’ labels, the strongest warnings for prescription drugs the agency can require, were designed to ‘frighten women and to silence doctors.’

‘It warned of diseases and dangers that the data simply did not support. Bureaucrats at the FDA reacted out of fear, not gold standard science. And instead of correcting the record, the medical establishment doubled down in groupthink,’ said Kennedy. ‘The consequences have been devastating.’

Makary added that a 2002 study known as the Women’s Health Initiative — which fueled concerns about hormone therapy and breast cancer — was ‘misrepresented and created a fear machine.’

He wrote in a Monday op-ed in The Wall Street Journal hours before the official announcement that HRT, which ‘consists of estrogen and progesterone (or estrogen alone for women who have had a hysterectomy),’ is a ‘breakthrough for many women.’

‘It alleviates the short-term symptoms of menopause, including hot flashes, night sweats, mood swings and weight gain, and when started within 10 years of menopause it has underappreciated long-term health benefits that even doctors may not be familiar with.’

The ‘black box’ warnings, which were first added in 2003, were based on misinterpreted data and discouraged millions of women from using HRT, according to the FDA commissioner.

Makary highlighted a 1991 UC San Diego review that found HRT may reduce fatal coronary events by about 50% and a 1996 study from the University of Southern California that found women using estrogen replacement therapy had a 35% lower risk of Alzheimer’s disease compared with nonusers.

FDA commissioner announces two new drugs for the treatment of menopausal symptoms

Kelly Casperson, a board-certified urologist, said at the HHS event that the FDA’s step to remove the ‘black box’ warning label would help ‘correct decades of misleading guidance.’

‘The FDA’s decision to remove the box warning is not just regulatory,’ she said. ‘It’s revolutionary.’

This post appeared first on FOX NEWS
Keep Reading
Politics

Senate hopes to blow through procedural hurdles in bid to reopen government

The ball is rolling to reopen the government, but there is still much left to do in the Senate before the record-shattering shutdown comes to an end.

Sunday night’s successful vote, which saw eight Senate Democrats splinter from Senate Minority Leader Chuck Schumer, D-N.Y., and their colleagues, was a massive step forward in the shutdown slog.

But there are several votes left and procedural roadblocks that could be weaponized that could grind the Senate’s march to advance its package to the House to a halt. If all 100 senators agree to fast-track the process, the package could move as quickly as Monday night. 

But if not, the bipartisan plan could stagnate in the upper chamber for several days. 

Senate Majority Leader John Thune, R-S.D., was optimistic that the Senate could finish its work Monday night but said that would be up to Senate Democrats.

‘Obviously, there are objections from the left, but as long as the votes are there to proceed, we will move forward, and hopefully without a lot of disruption or delay or fanfare right now,’ Thune said. ‘The point is, we are on a path to get the government reopened, and we should try to get it done as soon as possible.’

Schumer didn’t say whether Democrats would block any attempt to move the process along but did blame President Donald Trump and Republicans for the shutdown, which stretched into its 41st day on Monday.

The core of Democrats’ shutdown demands rested on a guarantee that expiring Obamacare subsidies would be dealt with before Schumer released the votes to reopen the government. But, the deal that was struck among bipartisan negotiators only reaffirmed Senate Majority Leader John Thune’s, R-S.D., earlier promise of a vote once the shutdown ended.

‘Democrats demanded that we find a way to fix this crisis and quickly,’ Schumer said. ‘But Republicans have refused to move an inch, so I cannot support the Republican bill that’s on the floor, because it fails to do anything of substance to fix America’s healthcare crisis.’

Whether Senate Democrats are in line with a cohesive strategy to block the package remains to be seen. But Sen. Ruben Gallego, D-Ariz., told Fox News Digital that he ‘didn’t hear anything’ about objections or blocks during the Democratic caucus’ closed-door meeting Sunday night.

‘I think a lot of us are just kind of taking in the information we heard today, talking to each other as Senate colleagues, and then we’re gonna make determinations later,’ he said.

And Sen. Bernie Sanders, I-Vt., who was furious at the outcome of the deal, appeared to put any chance of him objecting on ice.

‘I understand that the way the process has been developed, it is impossible to delay the votes that are going to take place,’ Sanders said. ‘And if that were not the case, that is certainly what I would do.’

Still, there is a worry that there may be some dissension within the GOP’s ranks from Sen. Rand Paul, R-Ky.

Paul is unhappy with the addition of language in the three-bill spending package that he argued would kneecap the hemp industry in his state, which played out in a battle between him and fellow Kentucky Republican Sen. Mitch McConnell earlier this year.

A spokesperson for Paul told Fox News Digital that Paul affirmed ‘his commitment to reopening the government without delay. However, he objects to the inclusion of provisions in the government-funding package that unfairly target Kentucky’s hemp industry — language that is unrelated to the budget and the government-reopening goal.’

And Paul further doused the notion that he would object with cold water, noting that he had filed an amendment to strike the provision in the bill.

‘Just to be clear: I am not delaying this bill,’ he said on X.

This post appeared first on FOX NEWS
Keep Reading
Investing

Nextech3D.ai Announces CEO Evan Gappelberg Acquires 550,000 Shares of Company Stock In Open Market Buys

Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:1SS), an AI-first technology company specializing in AI event management through its flagship Map D and Eventdex platforms, 3D modeling, and spatial computing, is pleased to announce that CEO Evan Gappelberg (the ‘Acquirer’) has purchased a total of 550,000 shares (the ‘Subject Shares’) through open market buys with an average purchase price of $0.10/ USD or $0.14 CAD per share.

Nextech AR CEO Evan Gappelberg commented, ‘I continue to invest and buy Nextech shares because I’m extremely excited about our business prospects, and I don’t believe that our current share price reflects the upside potential of our businesses. He continues ‘I’m very optimistic about our growth in 2026 and I’m investing today because I see many years of strong forward growth ahead for our businesses.’

The Acquirer acquired ownership and control of 550,000 Subject Shares in the open market buys. When added to his existing shareholdings of the Company which consist of an aggregate of 28,450,776 common shares, the Acquirer’s total, post-acquisition holdings of common shares is 29,000,776 common shares.

The holdings of securities of the Company by the Acquirer are managed for investment purposes, and the Acquirer and/or its joint actors could increase or decrease their respective investments in the Company at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor.

For further information, please contact:

About Nextech3D.ai

Nextech3D.ai (OTCQX: NEXCF | CSE: NTAR | FSE: 1SS) is an AI-first technology company developing advanced solutions for event management, 3D modeling, and spatial computing. Through its flagship Map D and Eventdex platforms, Nextech3D.ai powers thousands of events annually with interactive floor mapping, registration, ticketing, mobile apps, AI matchmaking, and now, blockchain ticketing and accreditation.

For further information, please visit: www.Nextech3D.ai.

Investor Relations: investors@nextechar.com

For more information, visit Nextech3D.ai.

Sign up for Investor News and Info – Click Here

For more information and full report go to

https://www.sedarplus.ca

For further information, please contact:

Nextech3D.ai
Evan Gappelberg / CEO and Director
866-ARITIZE (274-8493)

Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute ‘forward-looking information’ under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, ‘will be’ or variations of such words and phrases or statements that certain actions, events or results ‘will’ occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws


Click here to connect with Nextech3D.ai (CSE:NTAR,OTCQB:NEXCF,FSE:1SS) to receive an Investor Presentation

Source

This post appeared first on investingnews.com
Keep Reading
Politics

Johnson orders lawmakers back to DC ‘right now’ as shutdown sparks travel chaos

Speaker Mike Johnson, R-La., is sending a critical warning to House lawmakers as the government shutdown continues to wreak havoc on air travel.

‘As of Sunday, nearly half of all domestic flights and U.S. flights were either canceled or delayed, and it’s a very serious situation,’ Johnson said in comments to reporters on Monday.

‘So I’m saying that, by way of reminder, I’m stating the obvious, to all my colleagues, Republicans and Democrats in the House, you need to begin right now returning to the Hill. We have to do this as quickly as possible.’

The House leader was referring to taking up the Senate’s bipartisan measure to finally end the government shutdown, now on its 41st day.

The Federal Aviation Administration (FAA) is expected to reduce air travel at the nation’s 40 busiest airports by 6% as of Tuesday, amid widespread staffing shortages that have been attributed to the shutdown.

Thousands of federal employees have been furloughed as agencies and critical programs run low on funds, while government workers deemed ‘essential’ have been forced to work without pay for weeks.

People in the latter group include air traffic controllers and Transportation Security Administration (TSA) officers, many of whom have been forced to take second jobs and call out sick to make ends meet.

‘The problem we have with air travel is that our air traffic controllers are overworked and unpaid, and many of them have called in sick. That’s a very stressful job, and even more stressful, exponentially, when they’re having trouble providing for their families. And so air travel has been grinding to a halt in many places,’ Johnson said on Monday.

He delivered a statement to the press less than 12 hours after the Senate broke its weeks-long impasse on the shutdown, with eight Senate Democrats joining the GOP to overcome a filibuster.

Johnson told Fox News Digital exclusively earlier Monday that he would call the House back ‘immediately’ upon Senate passage of the bill — which he suggested could come sooner rather than later.

‘We’re going to get everybody back on a 36-hour notice, so it’ll be happening early this week,’ Johnson said.

The House has not been in session since Sept. 19, when lawmakers there first passed a bill to avert a shutdown by extending current federal funding levels through Nov. 21. Democrats rejected that deal, however, kicking off weeks of a worsening impasse where millions of Americans’ federal benefits and air travel were put at risk.

This post appeared first on FOX NEWS
Keep Reading